Momenta Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge
Massachusetts
02142
U.S.A.
Phone:
617-491-9700
Fax:
617-621-0431
|
Momenta was founded in 2001 based on technology developed at The Massachusetts Institute of Technology (MIT) for the precise sequencing of complex sugar molecules. This original technology platform and the resulting improvements have driven the company from a small, development-stage start-up to a public company with a leadership position in the analysis and design of complex products. Momenta currently employs a strategy unlike any other company in the biotechnology sector. By utilizing its technology platform to target three separate markets (complex generics, follow-on biologics, and novel drugs) the company spreads its risk while setting the stage for success in multiple product areas.
Momenta’s approach to drug development, linking structure with function,has yielded a diversified product pipeline consisting of both generic and novel complex mixture drugs.We are applying our technology to cellular polysaccharides suchasheparan-sulfate proteoglycans,or HSPGs, polypeptides and proteins. In July 2010, Momenta announced FDA approval for acomplex mixture drug, enoxaparin sodium injection, a generic version of Lovenox®,partnered with Sandoz and developed using our ground-breaking scientific expertise. The current pipeline also includes a generic version of Copaxone®, currently under FDA review, as well as two novel agents and an emerging portfolio of follow-on biologics.
Momenta currently employs 190 people and is headquarterd in Cambridge, MA.
Email:
info@momentapharma.com
Ownership:
Public
Web Site:
Momenta Pharmaceuticals, Inc.
Employees:
190
Symbol: MNTA
|